febuxostat has been researched along with Hyperuricemia in 305 studies
*Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (9.51) | 29.6817 |
| 2010's | 165 (54.10) | 24.3611 |
| 2020's | 111 (36.39) | 2.80 |
| Authors | Studies |
|---|---|
| B-Rao, C; Bahirat, U; Brahma, MK; Deshmukh, NJ; Dixit, A; Doshi, L; Ghosh, U; Katkar, KV; Keche, A; Khanna, S; Korde, V; Kulkarni-Almeida, A; Nemmani, KV; Shah, P; Sharma, R; Sivaramakrishnan, H; Srivastava, A | 1 |
| B-Rao, C; Bahirat, U; Bajaj, K; Brahma, MK; Burudkar, S; Damre, A; Desai, A; Deshmukh, NJ; Dixit, A; Doshi, L; Ghosh, U; Keche, A; Khanna, S; Kulkarni-Almeida, A; Nemmani, KV; Shah, P; Sharma, R; Sivaramakrishnan, H; Srivastava, A; Tannu, P | 1 |
| Chen, G; Edfeldt, F; Evenäs, J; Gränse, M; Lepistö, M; Li, C; Li, X; Liao, Y; Lundquist, B; Lv, G; Narjes, F; Rönnholm, A; Svitacheva, N; Synnergren, A; Tjörnebo, A; Varga, M; Wang, J; Wei, M; Wright, J; Yue, S | 1 |
| Jang, JW; Jung, SH; Kim, GT; Kim, TH; Park, H; Park, WS; Song, JU | 1 |
| Chen, H; Li, J; Li, Z; Liu, X; Wu, F; Zhang, L; Zou, Y | 1 |
| Bao, Z; Dai, X; Duan, Y; Mao, Q; Wang, S; Yang, Y; Zhang, B | 1 |
| Li, J; Li, X; Li, Y; Zhang, L; Zhou, H; Zhu, X | 1 |
| Dai, R; Dai, X; Duan, Y; Gao, J; Li, J; Li, Q; Lin, F; Mao, Q; Wang, S; Yang, Y; Zhang, B; Zhang, P | 1 |
| Cheng, H; Tian, J; Xiao, Z; Yang, Y; Ye, F; Zhang, L | 1 |
| Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 2 |
| Azushima, K; Kanaoka, T; Kinguchi, S; Okami, N; Tamura, K; Tsukamoto, S; Uneda, K; Wakui, H; Yamada, T; Yamaji, T | 1 |
| Akasaki, Y; Eguchi, K; Fukumoto, Y; Kamiya, H; Kario, K; Kusunose, K; Node, K; Sata, M; Tanaka, A; Teragawa, H; Yamada, H; Yoshida, H | 1 |
| Kashiwagi, T; Sakai, Y; Yamada, T | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Konishi, M; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
| Afinogenova, Y; Danve, A; Neogi, T | 1 |
| Ishibashi, T; Kobayashi, A; Konno, I; Kunii, H; Machii, H; Miyamoto, T; Nakazato, K; Niizeki, T; Nozaki, N; Suzuki, S; Takeishi, Y; Tsuda, A; Tsuda, T; Yamaguchi, O; Yamaki, T; Yokokawa, T; Yoshihisa, A | 1 |
| Chen, S; Deng, W; Huang, Q; Huang, Y; Huang, Z; Lee, PY; Li, T; Zheng, S | 1 |
| He, Z; Li, M; Ma, G; Teng, W; Xia, Z; Zhai, X | 1 |
| Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR | 1 |
| Eguchi, K; Fukumoto, Y; Ishizu, T; Kario, K; Kato, T; Node, K; Ohishi, M; Shiina, K; Takase, B; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Yoshida, H | 1 |
| Hosoya, T; Iwasa, N; Kataoka, H; Kimura, K; Mochizuki, T; Nitta, K; Ohara, M; Tsuchiya, K; Tsuruta, Y; Yoshida, R | 1 |
| Chin-Kanasaki, M; Imamura-Uehara, Y; Kato, K; Kume, S; Kuwagata, S; Maegawa, H; Nakagawa, Y; Ohno, S; Takeda, N; Yamahara, K; Yasuda-Yamahara, M | 1 |
| Hamasaki, S; Inoue, T; Ishizu, T; Kato, T; Node, K; Tanaka, A; Toyoda, S; Ueda, S; Watarai, M; Yoshida, H | 1 |
| Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB | 1 |
| Gruber, F; Kossmeier, M; Leitner, S; Litschauer, B; Reichardt, B; Sibinovic, S; Weisshaar, S; Wolzt, M | 1 |
| Gu, M; Kong, W; Yu, X; Zhang, L; Zhu, Y; Zou, Y | 1 |
| Deng, JH; Zhang, JX | 1 |
| Kawada, T | 2 |
| Burianov, OA; Danyliuk, SV; Khimion, LV; Nayshtetik, IM; Rotova, SO; Smiyan, SI; Trofanchuk, VV | 1 |
| Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X | 1 |
| Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H | 1 |
| Bao, S; Bian, X; Dai, L; Huang, J; Ma, J; Yu, Q; Zhang, A | 1 |
| Deng, JH; Zhang, JX; Zhong, GW | 1 |
| Choi, SR; Ha, YJ; Han, M; Kang, EH; Lee, EB; Lee, YJ; Shin, A | 1 |
| Kobayashi, Y; Koide, Y; Matsunaga, K; Node, K; Saito, Y; Tanaka, A; Uchida, D; Ueyama, C; Yokota, N; Yoshida, H | 1 |
| Cao, Y; Deng, Y; Jiang, X; Li, C; Li, X; Lin, P; Ma, Y; Sun, F; Tao, Y; Wang, C; Yu, Q; Zhu, Y | 1 |
| Hou, C; Li, Y; Ren, J; Sha, W; Yao, M | 1 |
| Cheng, H; Hou, X; Li, X; Nan, G; Ren, L; Tian, J; Xiao, Z; Yan, D; Yang, Y; Ye, F | 1 |
| Cai, Y; Cai, Z; Chen, T; Huang, X; Mi, X; Shui, G; Wang, F | 1 |
| Meng, J; Xu, C | 1 |
| Choi, E; Jeong, H; Kim, B; Suh, A; Yoo, M | 1 |
| Cao, B; Yang, N | 1 |
| Chen, M; Cui, R; Dai, SM; Du, Y; Tong, Q; Wang, SI; Wei, JC | 1 |
| Cui, J; Hou, J; Wang, W; Zhang, X | 1 |
| Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R | 1 |
| Douguchi, S; Hosoya, M; Katoh, M; Ofuchi, K; Osonoi, T; Saito, M | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kohagura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
| Du, B; Lin, T; Mu, L; Shang, Q; Wang, X; Zhang, L | 1 |
| Tamura, K; Tsukamoto, SI; Wakui, H | 1 |
| Bando, YK; Fujii, Y; Kadokami, T; Koide, H; Murohara, T; Node, K; Nomura, S; Saito, M; Sano, H; Tanaka, A; Teragawa, H; Ueda, T; Yoshida, H | 1 |
| Mironova, OI | 1 |
| Do, JY; Kang, SH; Kim, BY; Kim, GO; Son, EJ | 1 |
| Chen, H; Chen, L; Ding, R; Hu, X; Jiang, F; Li, X; Li, Y; Liu, K; Peng, Q; Wu, J; Xiong, T; Zhou, Y | 1 |
| Arima, H; Funakoshi, R; Iseki, K; Ishida, A; Kinjyo, K; Kochi, M; Kohagura, K; Nakamura, T; Ohya, Y; Sakima, A; Satoh, A; Tana, T; Yamazato, M; Zamami, R | 1 |
| Inkong, P; Nata, N; Ninwisut, N; Satirapoj, B; Supasyndh, O | 1 |
| Abdel Moneim, AE; Daabees, HG; Elagawany, M; Rashad, AY; Rostom, SAF; Shahin, M | 1 |
| Bohra, GK; Kumar, D; Meena, DS | 1 |
| Oyagüez, I; Pérez-Ruiz, F; Presa, M | 1 |
| Asano, T; Fujishiro, M; Inoue, MK; Kikuchi, T; Kushiyama, A; Masaki, T; Matsunaga, Y; Mizuno, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Takahashi, M; Ueda, K; Yamamotoya, T | 1 |
| Anderson, GF; Chang, SH; Chen, YC; Hsiao, CY; Hsu, YO; Huang, YT; Hung, CC; Kuo, CF; Kuo, G; Lee, CC; Lin, CY; Lin, HL; Lin, WT; Tian, YC; Tsai, CY; Wu, CY; Wu, IW; Yang, CC; Yang, CW; Yang, HY; Yen, TH | 1 |
| Peng, Q; Wan, D; Wang, X; Yang, G; Zhang, X | 1 |
| Yang, AY | 1 |
| Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S | 1 |
| Kuriyama, S | 1 |
| Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG | 1 |
| Abhishek, A | 1 |
| Asad, A; Batra, S; Ochani, RK; Yasmin, F | 1 |
| Hoshide, S; Kabutoya, T; Kario, K; Ueno, H | 1 |
| Han, H; Li, X; Tian, J; Yan, Z; Ye, F; Zhang, X | 1 |
| Chen, G; Honda, M; Kaneko, S; Matsui, C; Mizukoshi, E; Nagashimada, M; Nagata, N; Ni, Y; Nishikawa, T; Ota, T; Sakai, Y; Shimakami, T; Shirakura, T; Xu, L; Yamashita, T; Zhuge, F | 1 |
| Furuno, K; Hosoya, T; Kanda, S | 1 |
| Azar, A; Koenig, D; Royer, C | 1 |
| Bathini, T; Chang, YT; Cheungpasitporn, W; Chewcharat, A; Crisafio, A; Mao, MA; Thongprayoon, C | 1 |
| Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW | 1 |
| Cao, L; Wan, WG; Xue, Y; Yang, X; Zhao, L; Zhao, TY; Zhu, XX; Zou, HJ | 1 |
| Abe, T; Ito, S; Kikuchi, K; Kudo, M; Maeda, Y; Matsuhashi, T; Mishima, E; Mori, T; Nakajima, Y; Oikawa, Y; Sohara, E; Suzuki, T; Toyohara, T; Uchida, S | 1 |
| Hao, Z; Jie, S; Ke, L; Wentao, H; Xiaokang, L; Yunhua, M | 1 |
| Eguchi, K; Higashi, Y; Ishibashi, R; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kario, K; Kato, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, JI; Sata, M; Sezai, A; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamada, H; Yokote, K | 1 |
| Gu, SW; Huang, YY; Jiang, ZY; Ye, Z; Zhao, L | 1 |
| Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH | 1 |
| Brown, JN; Hu, AM | 1 |
| Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF | 1 |
| Arai, H; Ishimaru, Y; Kitamura, M; Maeda, K; Matsumura, K; Mori, T; Nishino, T; Obata, Y; Sohara, E; Uchida, S; Umene, R; Uramatsu, T | 1 |
| Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M | 1 |
| Chen, Q; Fan, S; Gao, Y; Hu, H; Shi, X; Wang, P; Yao, J | 1 |
| Singh, JA | 3 |
| Hsu, PK; Lee, YH; Wei, JCC | 1 |
| Chung, WH; Ma, KS; Wei, JC | 1 |
| Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G | 1 |
| Eliseev, MS; Novikova, AM | 1 |
| Jatuworapruk, K; Lertnawapan, R | 1 |
| Hsu, CN; Huang, YB; Lee, CT; Peng, YL; Tain, YL; Wen, YH; Yang, YH | 1 |
| Andrés, M; Blanco Cáceres, BA; Calvo-Aranda, E; Diaz-Torne, C; Pascual, E; Pérez Ruiz, F; Prada-Ojeda, A; Quilis, N; Sivera, F; Vela, P | 1 |
| Bang, D; Curovic, F; Igel, TF; Katz, SD; Krasnokutsky, S; Lazaro, D; Oh, C; Pike, VC; Pillinger, MH; Romero, AG; Shah, B; Toprover, M | 1 |
| Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B | 1 |
| Barrientos-Regala, M; Castillo, RR; Macabeo, RA; Pestaño, NS; Punzalan, FER; Ramirez-Ragasa, R; Tumanan-Mendoza, B | 1 |
| Lagumdzija, D; Muratovic, S; Omerovic, N; Pehlivanovic, B; Skrbo, S; Ziga-Smajic, N | 1 |
| Doi, Y; Fukae, S; Ikeda, S; Kawano, H; Koga, S; Maemura, K; Minami, T; Nakata, T; Tsuneto, A; Yonekura, T | 1 |
| Johansson, S; Leander, J; Rekić, D | 1 |
| Alqahtani, A; Balakumar, P; Dhanaraj, SA; Khan, NA; Mahadevan, N | 1 |
| Chen, W; Ding, J; Feng, Q; Huang, N; Jiang, L; Mao, H; Yang, X; Yu, X; Zhou, Q | 1 |
| Borghi, C; Cicero, AFG; Cincione, RI; Fogacci, F; Tocci, G | 1 |
| Dronamraju, N; Erlandsson, F; Goldwater, R; Han, D; Johansson, S; Johnsson, E; Oscarsson, J; Parkinson, J; Stack, AG | 1 |
| Hill-McManus, D; Hughes, DA | 1 |
| Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB | 1 |
| Bandyopadhyay, D; Deedwania, P; Fonarow, GC; Ghosh, RK; Gupta, M; Hajra, A; Kaul, S; Klein, A; Lavie, CJ; Mamas, M; Roddy, E | 1 |
| Choi, HK; Solomon, DH; Yoshida, K | 1 |
| Abe, Y; Fukumoto, Y; Hisatome, I; Hongou, M; Hoshide, S; Kario, K; Kasai, T; Kiuchi, M; Kiyosue, A; Kuga, H; Kuramochi, J; Miyazaki, S; Nishizawa, M; Ohtani, H; Tomita, F; Yasu, T | 1 |
| Borghi, C; Cicero, AFG; Fogacci, F; Kuwabara, M | 1 |
| Estiverne, C; Mount, DB | 1 |
| Huang, X; Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Yi, HK; Zhang, JW | 1 |
| Tausche, AK | 1 |
| Badve, SV; Johnson, DW; Tiku, A | 2 |
| Choudhary, D; Joshi, G; Kumar, S; Sharma, N | 1 |
| Hosoya, T; Ishikawa, T; Takahashi, T; Taniguchi, T | 1 |
| Cheng, R; Gao, L; Lu, Y; Pan, Y; Wang, B | 1 |
| Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L | 1 |
| Deeks, ED | 1 |
| Hayashi, M; Kikuchi, R; Matsushita, T; Murohara, T; Nakamura, S; Nakayama, T; Niwa, T; Shoaib Hamrah, M; Takeshita, K; Uchida, Y; Wu Cheng, X; Wu, H; Yamamoto, K; Yisireyili, M | 1 |
| Neogi, T; Vargas-Santos, AB | 1 |
| D Hayashi, R; Fujishima, Y; Fukuda, S; Funahashi, T; Ichida, K; Imagawa, A; Kimura, T; Kita, S; Kozawa, J; Maeda, N; Matsuoka, TA; Nishizawa, H; Otsuki, M; Shimomura, I; Taniguchi, A; Yamaoka, M | 1 |
| Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M; Uzu, T | 1 |
| Fan, CX; Li, L; Liang, YL; Lin, ZM; Liu, XN; Qu, JC; Xu, X; Zhang, RS; Zhao, HY; Zhao, L; Zhu, KS | 1 |
| Harada, M; Hashimoto, K; Kamijo, Y; Yamada, Y; Yamaguchi, A | 1 |
| Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A | 1 |
| Mitsuboshi, S; Nagai, K; Okajima, H; Yamada, H | 1 |
| Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U | 1 |
| Cimmino, MA; Cutolo, M; Perez-Ruiz, F | 1 |
| Borghi, C; Bove, M; Cicero, AFG | 1 |
| Feig, DI; Gunawardhana, L; Hunt, B; McLean, L; Palmer, RN; Punzi, HA; Whelton, A | 1 |
| Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC | 1 |
| Baek, CH; Han, DJ; Kim, H; Park, SK; Yang, WS | 1 |
| Balia, F; Borrelli, S; De Nicola, L; De Stefano, T; Garofalo, C; Minutolo, R; Nettuno, F; Pacilio, M; Sagliocchi, A; Scarpati, L; Sguazzo, A; Vinci, G; Vita, C | 1 |
| Treviño-Becerra, A | 1 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Madero, M; Ramirez-Sandoval, JC | 1 |
| Aschenbrenner, DS | 1 |
| Aksenov, S; Eriksson, UG; Peck, CC; Stanski, DR | 1 |
| Lioté, F; Pascart, T | 1 |
| Basile, M; Cicchetti, A; Drago, C; Rolli, FR; Ruggeri, M | 1 |
| Hu, K; Liu, J; Tang, Y; Wang, J; Xu, J; Zeng, XX; Zhou, X; Zhu, L | 1 |
| Maalouf, NM; Marin, M | 1 |
| Cheng, H; Liu, J; Liu, W; Yan, D; Zhang, Y; Zuo, X | 1 |
| Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H | 1 |
| Janssen, CA; Krol, M; Oude Voshaar, MAH; van de Laar, MAFJ; Vonkeman, HE | 1 |
| Cho, YS; Han, N; Kim, YS; Kwak, CH; Oh, JM; Sohn, M | 1 |
| Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X | 1 |
| Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X | 1 |
| Choi, H; Dalbeth, N; Neogi, T; Stamp, L; Terkeltaub, R | 1 |
| Echizen, H; Hirai, T; Itoh, T; Kimura, T | 1 |
| Tian, JY; Xiao, ZY; Yan, DA; Ye, F; Zhang, L | 1 |
| Desai, RJ; Kang, EH; Kim, SC; Liu, J; Neogi, T; Solomon, DH; Zhang, M | 1 |
| Baunthiyal, M; Gupta, A; Pathak, RK; Shukla, R | 1 |
| Dalbeth, N; Robinson, PC | 1 |
| Cleveland, JD; Singh, JA | 1 |
| Fukushima, A; Kinugawa, S; Murohara, T; Okumura, T; Tsutsui, H; Yokota, T | 1 |
| Cheetham, TC; Levy, G; Rashid, N; Shi, JM | 1 |
| Wang, S | 1 |
| Bettiol, A; Crescioli, G; Cricelli, C; Lapi, F; Lombardi, N; Marconi, E; Medea, G; Parretti, L; Vannacci, A | 1 |
| Robinson, PC | 1 |
| Chen, P; Chen, X; Fu, Q; Gao, X; Li, J; Liu, L; Shen, X; Wang, C | 1 |
| Lee, JW; Lee, KH | 1 |
| Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 2 |
| Borghi, C; Cicero, AFG; Cosentino, ER; Degli Esposti, D; Kuwabara, M | 1 |
| Gupta, MK; Singh, JA | 1 |
| Ješina, P; Pavelcova, K; Pavelka, K; Pavlikova, M; Stiburkova, B | 1 |
| Kim, JM; Kim, SH; Lee, SY; Son, CN | 1 |
| Ahn, C; Bae, EH; Choi, HS; Kim, CS; Kim, SW; Kim, YS; Ma, SK; Oh, KH; Oh, TR; Sung, SA | 1 |
| Li, Y; Liu, M; Lu, Y; Meng, J; Zhang, X | 1 |
| Kang, EH; Kim, SC | 1 |
| Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML | 1 |
| Von Zingel, M | 1 |
| Hosoya, T; Kobayashi, S; Ogura, M | 1 |
| Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I | 1 |
| Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG | 1 |
| Ohno, I | 1 |
| Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S | 1 |
| Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S | 1 |
| Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH | 1 |
| Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N | 1 |
| Berns, JS; Wilson, FP | 1 |
| Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T | 1 |
| Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X | 1 |
| Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT | 1 |
| Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N | 1 |
| Bae, EJ; Chang, SH; Cho, HS; Jang, HN; Kang, Y; Kim, MJ; Park, DJ; Yun, S | 1 |
| Aoki, T; Hishida, M; Maekawa, M; Morinaga, T; Tamai, H; Tomida, H | 1 |
| Fuchinoue, S; Nakajima, I; Teraoka, S; Tojimbara, T; Yashima, J | 1 |
| Espinoza, LR; Grewal, HK; Martinez, JR | 1 |
| Bocale, R; Desideri, G; Ferri, C; Grassi, D; Pontremoli, R | 1 |
| Becker, MA; Chaichian, Y; Chohan, S | 1 |
| Banse, C; Fardellone, P; Paccou, J | 1 |
| Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A | 1 |
| Jansen, TL | 1 |
| Ohya, M; Shigematsu, T | 1 |
| De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; Jennings, CG; MacDonald, TM; Mackenzie, IS; McMurray, J; Nuki, G; Perez Ruiz, F; Ralston, S; Walters, M; Webster, J | 1 |
| Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y | 1 |
| Hayashi, H; Hayashi, T; Hikosaka, S; Mizuno, T; Murase, M; Nagamatsu, T; Shimabukuro, Y; Takahashi, K; Yamada, S; Yuzawa, Y | 1 |
| Brucato, AL; Corrao, S; Di Corato, P; Djade, CD; Franchi, C; Ghidoni, S; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M | 1 |
| Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H | 1 |
| Fujimori, S; Hidaka, Y; Higami, K; Hosoya, T; Inaba, M; Ishimura, E; Kakuda, H; Mineo, I; Moriwaki, Y; Nishikawa, H; Ohtawara, A; Ooyama, H; Taniguchi, A; Ueda, T; Yamamoto, T; Yamanaka, H; Yamauchi, T | 1 |
| Asahi, K; Hayashi, Y; Kanno, M; Kimura, H; Nakayama, M; Tanaka, K; Tani, Y; Terawaki, H; Watanabe, K; Watanabe, T | 1 |
| Frampton, JE | 1 |
| Abe, Y; Fukui, T; Maruyama, M; Yamauchi, K; Yasuda, T; Yoshitaka, S | 1 |
| Akiba, T; Itabashi, M; Kikuchi, K; Moriyama, T; Nitta, K; Sasaki, Y; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K | 1 |
| Asano, T; Fujishiro, M; Fukushima, T; Kamata, H; Kanaoka, R; Katasako, A; Kushiyama, A; Matsunaga, Y; Mori, K; Nakatsu, Y; Sakoda, H; Seno, Y; Yamamotoya, T | 1 |
| Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y | 1 |
| Nishizawa, T; Nomura, S; Taniura, T | 1 |
| Araki, H; Chisaki, Y; Hira, D; Maegawa, H; Morita, SY; Noda, S; Terada, T; Uzu, T; Yano, Y | 1 |
| Chatterjee, S; Golay, V; Pandey, R; Raychaudhury, A; Sircar, D; Waikhom, R | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Cheetham, TC; Levy, G | 1 |
| Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH | 1 |
| Reuss-Borst, MA | 1 |
| Carcedo, D; Díaz-Torné, C; Perez-Ruiz, F | 1 |
| Aibibula, Z; Ailixiding, M; Asou, Y; Hara, Y; Iwata, M; Okawa, A; Piao, J | 1 |
| Chinchilla, SP; Perez-Ruiz, F; Urionaguena, I | 1 |
| Bäurle, A | 1 |
| Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T | 1 |
| Higa, A; Iseki, K; Ishida, A; Kohagura, K; Nagahama, K; Ohya, Y; Sakima, A; Tana, T; Yamazato, M | 1 |
| Bakinde, N; Mome, R | 1 |
| Filiopoulos, V; Hadjiyannakos, D; Vlassopoulos, D | 1 |
| Sircar, D | 1 |
| Haruyama, S; Nakamura, M; Nishio, D; Oda, T; Ohmori, S; Omoto, D; Sawada, Y; Yoshioka, M | 1 |
| Echizen, H; Hirai, T; Kimura, T | 1 |
| Andrés, M; Gil, S; Pascual, E; Quilis, N; Ranieri, L; Vela, P | 1 |
| Ako, J; Bando, YK; Eguchi, K; Higashi, Y; Inoue, T; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kuroyanagi, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H | 1 |
| Chen, C; Lü, JM; Yao, Q | 1 |
| Ahn, SM; Choi, SW; Hong, S; Kim, YG; Lee, CK; Lim, DH; Oh, JS; Yoo, B | 1 |
| Dalbeth, N; Stamp, L | 1 |
| Horii, M; Kobayashi, S; Kurokawa, Y; Yasu, T | 1 |
| Agrawal, A; Saigal, R | 1 |
| Chung, BH; Jin, J; Jin, L; Kim, HS; Lim, SW; Yang, CW | 1 |
| Arima, H; Hayashi, S; Ishizuka, A; Iwashima, Y; Kawano, Y; Kishida, M; Nakamura, S; Ohta, Y; Yoshihara, F | 1 |
| Stamp, LK | 1 |
| Hoshi, H; Kazama, JJ; Terawaki, H | 1 |
| Chen, LX; Schumacher, HR | 1 |
| Hair, PI; Keating, GM; McCormack, PL | 1 |
| Schlesinger, N | 2 |
| Edwards, NL | 2 |
| Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Yu, KH | 1 |
| Kirkpatrick, P; Pascual, E; Sivera, F; Yasothan, U | 1 |
| Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR | 1 |
| Keenan, RT; Pillinger, MH | 1 |
| Lioté, F; Perez-Ruiz, F; Scavulli, J; Terkeltaub, R; Zelman, D | 1 |
| Pandor, A; Stevenson, M | 2 |
| Hall, HA; Poon, SH; Zimmermann, B | 1 |
| Ernst, ME; Fravel, MA | 1 |
| Sundy, JS | 1 |
| Jansen, TL; Reinders, MK | 1 |
| Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF | 1 |
| Barrons, R; Love, BL; Snider, KM; Veverka, A | 1 |
| Quillen, DM | 1 |
| Graser, E; Pope, RS; Zychowicz, ME | 1 |
| Gunawardhana, L; Hunt, B; Macdonald, PA; Whelton, A; Zhao, L | 1 |
| Gray, CL; Walters-Smith, NE | 1 |
| Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL | 1 |
| Dubost, JJ; Mathieu, S; Soubrier, M | 1 |
| Doghramji, PP | 1 |
| Hosoya, T; Kamatani, N; Naoyuki, K; Tatsuo, H | 1 |
| Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H | 2 |
| Hosoya, T; Iwao, O; Ohno, I; Tatsuo, H | 1 |
| Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M | 2 |
| Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA | 1 |
| Schmidt, BM; Wagner, AD | 1 |
| Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA | 1 |
| Hunt, B; Jackson, RL; MacDonald, PA | 1 |
| Curiel, RV; Guzman, NJ | 1 |
| Manger, B | 1 |
| Isaka, Y; Kaimori, JY; Kawada, N; Kitamura, H; Moriyama, T; Rakugi, H; Takahara, S; Tsuda, H | 1 |
| Butani, L; Calogiuri, G; Di Leo, E; Ferrannini, A; Foti, C; Nettis, E | 1 |
| Keenan, RT | 1 |
| Lopez-Olivo, MA; Suarez-Almazor, ME; Tayar, JH | 1 |
| Akimoto, T; Horikoshi, R; Inoue, M; Kusano, E; Morishita, Y | 1 |
| Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W | 1 |
| Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A | 1 |
| Yamamoto, T | 1 |
| Bomalaski, JS; Clark, MA | 1 |
| Hoshide, S; Kamatani, N; Kobayashi, H; Komoriya, K; Kubo, J; Nakachi, T; Takeda, K; Tsuchimoto, M; Yamanaka, H | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL | 1 |
| Schumacher, HR | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Moreland, LW | 1 |
| Lee, SJ; Terkeltaub, RA | 1 |
| Ziegler, R | 1 |
| Bruce, SP | 1 |
| Abeles, AM; Pillinger, MH; Rosenthal, P | 1 |
| Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Zhao, L | 1 |
| Okamoto, K | 1 |
| Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Wessale, JL; Zhao, L | 1 |
81 review(s) available for febuxostat and Hyperuricemia
| Article | Year |
|---|---|
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2021 |
Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Network Meta-Analysis; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Update on gout management: what is old and what is new.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up | 2022 |
Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Topics: Allopurinol; Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid; Xanthine Oxidase | 2022 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Benzothiazoles; Drug Interactions; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Uric Acid; Uricosuric Agents | 2020 |
Debates in gout management.
Topics: Allopurinol; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Quality of Life | 2020 |
Successful Desensitization to Febuxostat in a Patient With Hypersensitivity to Allopurinol and Febuxostat and Review of the Literature.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2021 |
Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Observational Studies as Topic; Treatment Outcome; Uric Acid | 2020 |
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Humans; Hyperuricemia; Risk Assessment; Uric Acid | 2020 |
Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2020 |
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2021 |
The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Topics: Aged; Allopurinol; Biomarkers; Blood Pressure; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid | 2020 |
Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Topics: Animals; Biomarkers; Cytokines; Epithelial-Mesenchymal Transition; Febuxostat; Fibrosis; Gout Suppressants; Humans; Hyperuricemia; Inflammation Mediators; Kidney; Kidney Diseases; Oxidative Stress; Signal Transduction; Uric Acid | 2020 |
Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
Topics: Allopurinol; Benzaldehydes; Chronic Disease; Comorbidity; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyridines; Randomized Controlled Trials as Topic; Xanthine Oxidase | 2021 |
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.
Topics: Cardiovascular Diseases; Colchicine; COVID-19; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Pandemics | 2021 |
Medications for gout and its comorbidities: mutual benefits?
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Observational Studies as Topic; Symptom Flare Up | 2021 |
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Naphthalenes; Nitriles; Phenylacetates; Polyethylene Glycols; Probenecid; Propionates; Pyridines; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2021 |
The Management of Gout in Renal Disease.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2020 |
Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
Topics: Disease Progression; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Topics: Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Uricosuric Agents | 2021 |
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Myocardial Infarction | 2021 |
The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Topics: Allopurinol; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2021 |
Lesinurad: A Review in Hyperuricaemia of Gout.
Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Kidney; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2017 |
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Topics: Adult; Allopurinol; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2017 |
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Topics: Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
[Hyperuricaemia and Chronic Kidney Disease].
Topics: Allopurinol; Arteriosclerosis; Disease Progression; Febuxostat; Humans; Hypertension; Hyperuricemia; Observational Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors | 2018 |
Uric Acid: The Unknown Uremic Toxin.
Topics: Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney; Parenchymal Tissue; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Treatment of Hyperuricemia in Chronic Kidney Disease.
Topics: Allopurinol; Diet; Disease Progression; Exercise; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Life Style; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Weight Loss | 2018 |
Gout: state of the art after a decade of developments.
Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2019 |
Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic | 2018 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thioglycolates; Triazoles; Uric Acid | 2018 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2019 |
Cardiovascular Safety of Urate Lowering Therapies.
Topics: Allopurinol; Cardiovascular Diseases; Endothelium; Febuxostat; Gout; Gout Suppressants; Heart Failure; Humans; Hypertension; Hyperuricemia; Myocardial Infarction; Probenecid; Risk; Stroke; Uricosuric Agents; Xanthine Oxidase | 2019 |
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2019 |
[The cutting-edge of medicine; role of hyperuricemia in cardiorenal syndrome].
Topics: Cardio-Renal Syndrome; Febuxostat; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome | 2013 |
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Tumor lysis syndrome: new challenges and recent advances.
Topics: Acute Kidney Injury; Allopurinol; Bicarbonates; Buffers; Calcium; Diuretics; Enzyme Inhibitors; Febuxostat; Fluid Therapy; Humans; Hyperkalemia; Hyperphosphatemia; Hyperuricemia; Hypocalcemia; Renal Dialysis; Thiazoles; Tumor Lysis Syndrome; Urate Oxidase | 2014 |
Febuxostat: drug review and update.
Topics: Animals; Arthritis, Gouty; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hepatic Insufficiency; Humans; Hyperuricemia; Liver; Thiazoles; Xanthine Oxidase | 2014 |
Therapeutic approaches to chronic hyperuricemia and gout.
Topics: Allopurinol; Cardiovascular Diseases; Chronic Disease; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Life Style; Patient Education as Topic; Thiazoles; Xanthine Oxidase | 2014 |
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Febuxostat; Feeding Behavior; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Risk Reduction Behavior; Thiazoles; Urate Oxidase; Uricosuric Agents | 2014 |
Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.
Topics: Clinical Trials, Phase III as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2015 |
[Hyperuricemia. When and how to treat?].
Topics: Allopurinol; Evidence-Based Medicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Internationality; Practice Guidelines as Topic; Treatment Outcome; Uricosuric Agents | 2016 |
Febuxostat for the chronic management of hyperuricemia in patients with gout.
Topics: Drug Administration Schedule; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2016 |
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Topics: Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Reactive Oxygen Species; Risk Factors; Xanthine Dehydrogenase | 2016 |
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
Topics: Allopurinol; Asymptomatic Diseases; Drug Eruptions; Drug Hypersensitivity; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Uricosuric Agents; Urolithiasis | 2017 |
Pathogenesis and Clinical Management of Gouty Arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Gouty; Colchicine; Diet, Healthy; Febuxostat; Fluid Therapy; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Smoking Cessation; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2015 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care Planning; Probenecid; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2017 |
Febuxostat.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Molecular Structure; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Uric Acid | 2008 |
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
Topics: Animals; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patents as Topic; Thiazoles; Xanthine Oxidase | 2007 |
Febuxostat: a new treatment for hyperuricaemia in gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Febuxostat: a new agent for lowering serum urate.
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Liver Diseases; Thiazoles | 2009 |
Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Topics: Allopurinol; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Approach to the treatment of hyperuricemia.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2009 |
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Half-Life; Humans; Hyperuricemia; Thiazoles; Tissue Distribution; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 2009 |
Progress in the pharmacotherapy of gout.
Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Recombinant Fusion Proteins; Thiazoles; Uricosuric Agents | 2010 |
Management of hyperuricemia in gout: focus on febuxostat.
Topics: Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2010 |
New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.
Topics: Acute Disease; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Thiazoles; Urate Oxidase | 2010 |
Urate-lowering therapy for gout: focus on febuxostat.
Topics: Clinical Trials as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Thiazoles; Xanthine Oxidase | 2010 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Uricosuric Agents | 2010 |
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.
Topics: Biomedical Technology; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles | 2011 |
Febuxostat for treatment of chronic gout.
Topics: Allopurinol; Animals; Chronic Disease; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2011 |
[Treatment of gout].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents | 2011 |
Managing your patient with gout: a review of treatment options.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles | 2011 |
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
[Hyperuricemia, gout, pseudogout and concomitant diseases].
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chondrocalcinosis; Comorbidity; Diabetes Mellitus, Type 2; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Kidney Failure, Chronic; Thiazoles; Xanthine Oxidase | 2011 |
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Comorbidity; Contraindications; Febuxostat; Glucocorticoids; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Probenecid; PubMed; Renal Insufficiency, Chronic; Secondary Prevention; Thiazoles; Urate Oxidase | 2012 |
[Gout and other crystal-induced arthritides].
Topics: Absorptiometry, Photon; Aged; Allopurinol; Arthritis, Gouty; Chondrocalcinosis; Cross-Sectional Studies; Enzymes, Immobilized; Evidence-Based Medicine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Risk Factors; Thiazoles; Ultrasonography; Urate Oxidase | 2012 |
Safety of urate-lowering therapies: managing the risks to gain the benefits.
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Thiazoles; Uric Acid | 2012 |
Febuxostat for treating chronic gout.
Topics: Allopurinol; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Randomized Controlled Trials as Topic; Thiazoles | 2012 |
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2013 |
[Development antihyperuricemic candidates].
Topics: Animals; Drug Design; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Pyrazoles; Tetrazoles; Thiazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2003 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Losartan; Pyrazoles; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid; Xanthine Oxidase | 2004 |
Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Topics: Disease Management; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2005 |
New developments in clinically relevant mechanisms and treatment of hyperuricemia.
Topics: Febuxostat; Humans; Hyperuricemia; Prognosis; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2006 |
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Topics: Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2006 |
Hyperuricemia and gout: new insights into pathogenesis and treatment.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Thiazoles; Urate Oxidase; Uric Acid | 2007 |
[Inhibitors of xanthine oxidoreductase].
Topics: Allopurinol; Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyrazoles; Pyridines; Thiazoles; Xanthine Dehydrogenase | 2008 |
73 trial(s) available for febuxostat and Hyperuricemia
| Article | Year |
|---|---|
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2022 |
Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.
Topics: Awards and Prizes; Diastole; Febuxostat; Humans; Hyperuricemia; Natriuretic Peptide, Brain; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2022 |
Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.
Topics: Allopurinol; Febuxostat; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2021 |
Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
Topics: Combined Modality Therapy; Contrast Media; Coronary Angiography; Coronary Disease; Creatinine; Febuxostat; Fluid Therapy; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Lipocalin-2; Percutaneous Coronary Intervention; Treatment Outcome; Uric Acid | 2022 |
Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study.
Topics: Ankle Brachial Index; Atherosclerosis; Awards and Prizes; Carotid Artery Diseases; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Prospective Studies; Pulse Wave Analysis; Uric Acid; Vascular Stiffness; Xanthine Oxidase | 2022 |
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Topics: Creatinine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Proteinuria; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial.
Topics: Adult; Awards and Prizes; Carotid Artery Diseases; Carotid Intima-Media Thickness; Febuxostat; Humans; Hyperuricemia; Uric Acid | 2022 |
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.
Topics: Atherosclerosis; C-Reactive Protein; Febuxostat; Female; Humans; Hyperuricemia; Inflammation; Male; Treatment Outcome; Uric Acid | 2023 |
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospective Studies; Treatment Outcome; Uric Acid | 2022 |
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study.
Topics: Awards and Prizes; Blood Pressure; Carotid Intima-Media Thickness; Febuxostat; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2022 |
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
Topics: Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2023 |
Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
Topics: Actins; Animals; Cadherins; Caspases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Febuxostat; Fibronectins; Hyperuricemia; Inflammasomes; Interleukin-18; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Renal Insufficiency, Chronic; Uric Acid; Vimentin | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Treatment Outcome; Uric Acid | 2023 |
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2023 |
Effect of febuxostat on the level of malondialdehyde-modified low-density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study.
Topics: Carotid Artery Diseases; Cholesterol, LDL; Febuxostat; Humans; Hyperuricemia; Malondialdehyde; Oxidative Stress; Uric Acid | 2023 |
A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.
Topics: Colchicine; East Asian People; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Male; Treatment Outcome; Uric Acid; Uricosuric Agents | 2023 |
Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Topics: Benzbromarone; Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2023 |
Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.
Topics: C-Reactive Protein; Febuxostat; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid; Vascular Diseases | 2023 |
Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Topics: Aged; Antioxidants; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2020 |
Class effect of xanthine oxidase inhibitors on flow-mediated dilatation in hypertensive patients: A randomized controlled trial.
Topics: Aged; Allopurinol; Dilatation; Febuxostat; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Treatment Outcome; Xanthine Oxidase | 2020 |
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Topics: Adult; Aged; Benzothiazoles; Double-Blind Method; Febuxostat; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; Treatment Outcome; Uric Acid; Uricosuric Agents | 2020 |
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Single-Blind Method; Uric Acid | 2020 |
Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Topics: Adiponectin; Aged; Arginine; Benzbromarone; Cross-Over Studies; Endothelium, Vascular; Febuxostat; Female; Gout Suppressants; Humans; Hyperemia; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Treatment Outcome; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2020 |
Rationale and design for Lowering-hyperUricaemia treatment on cardiovascular outcoMes In peritoNeal diAlysis patients: a prospective, multicentre, double-blind, randomised controlled trial (LUMINA).
Topics: Double-Blind Method; Febuxostat; Humans; Hyperuricemia; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies | 2020 |
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Female; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Naphthalenes; Propionates; Pyridines; Treatment Outcome; United States; Uric Acid; Uricosuric Agents; Young Adult | 2021 |
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Topics: Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Nitriles; Pyridines; Treatment Outcome; Uric Acid | 2021 |
Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Topics: Adult; Aged; Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Cross-Over Studies; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Pyridines; Treatment Outcome; Uric Acid | 2017 |
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Joints; Magnetic Resonance Imaging; Male; Middle Aged; Synovitis; Treatment Outcome; Uric Acid | 2017 |
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; North America; Proof of Concept Study; Prospective Studies; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis.
Topics: Arthritis, Gouty; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Febuxostat; Female; Homeostasis; Humans; Hyperuricemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Systole; Uric Acid | 2018 |
Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Topics: Aged; Alpha-Globulins; Benzbromarone; Febuxostat; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Hyperuricemia; Kidney Calculi; Male; Middle Aged; Pilot Projects; Prospective Studies; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2018 |
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Time Factors; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Young Adult | 2018 |
Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF).
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Febuxostat; Female; Gout Suppressants; Heart Failure; Hospitalization; Humans; Hyperuricemia; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Peptide Fragments; Prospective Studies; Stroke Volume; Ventricular Function, Left | 2018 |
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2018 |
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Prospective Studies; Uric Acid | 2019 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Topics: Aged; Albuminuria; Allopurinol; Arachidonic Acid; Blood Pressure; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, LDL; Male; Middle Aged; Pulse Wave Analysis; Stroke Volume; Thiazoles; Uric Acid | 2013 |
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Prevalence; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Topics: Administration, Oral; Biomarkers; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Japan; Kidney; Prospective Studies; Renal Insufficiency, Chronic; Research Design; Risk Factors; Severity of Illness Index; Tablets; Thiazoles; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2014 |
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Remission Induction; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Thioglycolates; Triazoles; Uric Acid | 2014 |
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prospective Studies; Research Design | 2014 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Topics: Aged; Albuminuria; Allopurinol; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Renal Insufficiency, Chronic; Triglycerides; Uric Acid | 2015 |
Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
Topics: Adult; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Prevalence; Treatment Outcome; Uric Acid | 2015 |
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Albuminuria; beta 2-Microglobulin; Enzyme Inhibitors; Fatty Acid-Binding Proteins; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Uric Acid; Xanthine Oxidase | 2015 |
Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2015 |
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Topics: Administration, Oral; Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Time Factors; Treatment Outcome; Uric Acid | 2015 |
Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment.
Topics: Adult; Aged; Aged, 80 and over; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency; Retrospective Studies | 2015 |
Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Adult; Aged; Asymptomatic Diseases; Double-Blind Method; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; India; Male; Middle Aged; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2015 |
Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Renin-Angiotensin System; Risk Factors; Treatment Outcome; Xanthine Oxidase | 2015 |
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Topics: Administration, Oral; Adult; Alleles; Allopurinol; China; Febuxostat; Female; Gout; Gout Suppressants; HLA-B Antigens; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2016 |
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Topics: Aged; Aged, 80 and over; Brain Diseases; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Research Design; Single-Blind Method; Treatment Outcome; Uric Acid | 2017 |
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Neoplasms; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine Oxidase; Young Adult | 2016 |
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery, Common; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Risk Factors; Uric Acid; Xanthine Oxidase; Young Adult | 2016 |
Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Topics: Aged; Benzbromarone; Cross-Over Studies; Drug Therapy, Combination; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2017 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2008 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult | 2010 |
Renal function in gout: long-term treatment effects of febuxostat.
Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Thiazoles; Young Adult | 2011 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2010 |
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Oxypurinol; Renal Insufficiency; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2011 |
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Illinois; Male; Metabolic Diseases; Middle Aged; Obesity; Retrospective Studies; Sex Factors; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2012 |
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Liver Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2011 |
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2012 |
Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Topics: Area Under Curve; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Male; Oxygen; Thiazoles; Time Factors; Xanthine Dehydrogenase; Xanthine Oxidase | 2004 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
151 other study(ies) available for febuxostat and Hyperuricemia
| Article | Year |
|---|---|
Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.
Topics: Animals; Computer Simulation; Cytosine; Enzyme Activation; Enzyme Inhibitors; Hyperuricemia; Male; Oxonic Acid; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthine Oxidase | 2012 |
Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.
Topics: Administration, Oral; Animals; Cytosine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Hyperuricemia; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Rats, Wistar; Structure-Activity Relationship; Time Factors; Xanthine Oxidase | 2012 |
HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.
Topics: Animals; Binding Sites; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Inhibitors; Gout Suppressants; Half-Life; High-Throughput Screening Assays; Hyperuricemia; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidinones; Rats; Structure-Activity Relationship; Xanthine Oxidase | 2014 |
Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.
Topics: Administration, Oral; Animals; Binding Sites; Cattle; Drug Design; Enzyme Inhibitors; Half-Life; Hyperuricemia; Microsomes, Liver; Molecular Docking Simulation; Protein Structure, Tertiary; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hyperuricemia; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Oxonic Acid; Pyrazoles; Structure-Activity Relationship; Xanthine Dehydrogenase | 2017 |
Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Female; Hyperuricemia; Male; Mice; Mice, Inbred Strains; Molecular Structure; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthine Oxidase | 2019 |
Synthesis and bioevaluation of 1-phenylimidazole-4-carboxylic acid derivatives as novel xanthine oxidoreductase inhibitors.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hyperuricemia; Imidazoles; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Xanthine Dehydrogenase | 2020 |
Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.
Topics: Animals; Cattle; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Hyperuricemia; Male; Milk; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthine Oxidase | 2022 |
Identification of novel xanthine oxidase inhibitors via virtual screening with enhanced characterization of molybdopterin binding groups.
Topics: Enzyme Inhibitors; Humans; Hyperuricemia; Molecular Docking Simulation; Molybdenum Cofactors; Quantitative Structure-Activity Relationship; Xanthine Oxidase | 2022 |
Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease.
Topics: Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2022 |
Clinical characteristics of juvenile gout and treatment response to febuxostat.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Treatment Outcome | 2022 |
Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.
Topics: Adult; alpha-Galactosidase; Enzyme Replacement Therapy; Fabry Disease; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Proteinuria; Treatment Outcome; Uric Acid | 2022 |
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Hyperuricemia; Ischemic Stroke; Male; Retrospective Studies; Risk Factors; Uric Acid | 2022 |
Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2022 |
Febuxostat Use and Safety in Patients With Hyperuricemia.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2022 |
POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Lipolysis; Prospective Studies; Uric Acid; Xanthine Oxidase | 2022 |
The safety and urate-lowering efficacy of febuxostat in patients undergoing peritoneal dialysis: a retrospective single-arm cohort study of 84 patients.
Topics: Cohort Studies; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Peritoneal Dialysis; Retrospective Studies; Treatment Outcome; Uric Acid | 2022 |
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2022 |
Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
Topics: Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Myocardial Infarction; Treatment Outcome | 2022 |
A modified xanthine oxidase cell model for screening of antihyperuricemic functional compounds.
Topics: Adenosine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Hypoxanthines; Peptides; Uric Acid; Xanthine Oxidase | 2022 |
Discovery of novel 1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors with hypouricemic effects.
Topics: Animals; Enzyme Inhibitors; Febuxostat; Gout; Hyperuricemia; Mice; Triazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2022 |
Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Secondary Prevention; Treatment Outcome | 2023 |
`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
Topics: Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Republic of Korea; Retrospective Studies | 2023 |
Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study.
Topics: Adult; Allopurinol; Cohort Studies; Erectile Dysfunction; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male | 2022 |
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Febuxostat; Humans; Hyperuricemia; Indican; Prospective Studies; Uric Acid; Uricosuric Agents | 2022 |
Clinical observation of Febuxostat in the treatment of gout patients with different body fat levels.
Topics: Adipose Tissue; Febuxostat; Gout; Humans; Hyperuricemia; Treatment Outcome | 2023 |
Effects of Uric Acid-Lowering Therapy on the Kidney (HTR-2023-0096.R2).
Topics: Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid | 2023 |
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2023 |
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Treatment Outcome; Uric Acid | 2023 |
A New Avenue for Enhanced Treatment of Hyperuricemia and Oxidative Stress: Design, Synthesis and Biological Evaluation of Some Novel Mutual Prodrugs Involving Febuxostat Conjugated with Different Antioxidants.
Topics: Animals; Antioxidants; Drug Design; Febuxostat; Hyperuricemia; Oxidative Stress; Prodrugs; Rabbits | 2023 |
Acute severe gouty arthritis secondary to isotretinoin toxicity in a young male: a case report.
Topics: Acne Vulgaris; Adult; Arthritis, Gouty; Febuxostat; Humans; Hyperuricemia; Isotretinoin; Male | 2023 |
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Topics: Allopurinol; Cost-Benefit Analysis; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Spain; Thioglycolates; Triazoles | 2019 |
Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL2; Collagen; Diabetic Nephropathies; Febuxostat; Glucose Intolerance; Hyperglycemia; Hyperuricemia; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Kidney Glomerulus; Mice; Mice, Inbred C57BL; Mice, Obese; Oxidative Stress; Peptide Fragments; Uric Acid; Xanthine Oxidase | 2019 |
Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Databases, Factual; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Taiwan; Young Adult | 2020 |
Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Topics: Aged; Allopurinol; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Treatment Outcome | 2019 |
Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Topics: Adult; Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Emergency Service, Hospital; Ethnicity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Singapore; Treatment Outcome; Uric Acid | 2020 |
A word of caution regarding Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Drug-Related Side Effects and Adverse Reactions; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Pakistan; Xanthine Oxidase | 2019 |
Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Topics: Animals; Benzbromarone; Disease Models, Animal; Febuxostat; HEK293 Cells; Humans; Hyperuricemia; Kidney; Male; Mice, Inbred ICR; Organic Anion Transporters; Organic Cation Transport Proteins; Uric Acid | 2019 |
Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Topics: Allopurinol; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Febuxostat; Hyperuricemia; Insulin Resistance; Lipid Peroxidation; Liver; Macrophage Activation; Mice, Inbred C57BL; Molecular Targeted Therapy; Uric Acid; Xanthine Oxidase | 2020 |
Efficacy and tolerability of febuxostat in gout patients on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Retrospective Studies; Treatment Outcome; Uric Acid | 2021 |
HPRT-related hyperuricemia with a novel p.V35M mutation in HPRT1 presenting familial juvenile gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; Kidney Calculi; Kidney Diseases; Male; Mutation, Missense; Treatment Outcome; Young Adult | 2020 |
Febuxostat Promoted Dissolution of Radiolucent Nephrolithiasis in Patients with Hyperuricemia.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Nephrolithiasis; Retrospective Studies; Young Adult | 2020 |
The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout.
Topics: Adult; Asian People; China; Cohort Studies; Double-Blind Method; Ethnicity; Febuxostat; Female; Gout; Humans; Hyperuricemia; Interleukin-17; Interleukin-6; Male; Middle Aged; Placebos; Random Allocation; Treatment Outcome; Tumor Necrosis Factor-alpha; Uric Acid | 2020 |
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progression; Drug Prescriptions; Febuxostat; Female; Gout Suppressants; Heart Disease Risk Factors; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; Middle Aged; Protective Factors; Retrospective Studies; Risk Assessment; Stroke Volume; Time Factors; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Bartter syndrome representing digenic-based salt-losing tubulopathies presumably accelerated by renal insufficiency.
Topics: Adult; Bartter Syndrome; Chloride Channels; Diagnosis, Differential; Drug Therapy, Combination; Febuxostat; Female; Gitelman Syndrome; Gout Suppressants; Heterozygote; Humans; Hyperuricemia; Hypokalemia; Mutation; Phenotype; Potassium Chloride; Renal Insufficiency; Solute Carrier Family 12, Member 1; Treatment Outcome | 2020 |
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Febuxostat; Heart; Hyperuricemia; Kidney Diseases; Kidney Function Tests; Male; Myocardium; Nephrectomy; Oxidative Stress; Oxonic Acid; Protective Agents; Rats, Sprague-Dawley; Xanthine Oxidase | 2020 |
Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for a systematic review and meta-analysis.
Topics: Blood Pressure; Febuxostat; Humans; Hypertension; Hyperuricemia; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic | 2020 |
Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma
Topics: Aged; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
Confounding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Topics: Aged; Allopurinol; Ethnicity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu
Topics: Aged; Allopurinol; Ethnicity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Topics: Aged; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2020 |
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prevalence; Uric Acid | 2019 |
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Thailand; Thiazoles; Treatment Outcome; Uric Acid | 2021 |
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Taiwan; Uric Acid | 2020 |
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2022 |
Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Skin | 2022 |
Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation | 2020 |
Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Retrospective Studies; Time Factors; Triglycerides; Uric Acid | 2020 |
Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.
Topics: Body Weight; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male | 2021 |
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.
Topics: Allopurinol; Bayes Theorem; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Theory; Drug Development; Economics, Pharmaceutical; Febuxostat; Gout; Humans; Hyperuricemia; Investments; Models, Biological; Models, Economic; Reimbursement Mechanisms; Research Design; Sample Size; Uncertainty; Uric Acid | 2021 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2021 |
Inosine induces acute hyperuricaemia in rhesus monkey (
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Febuxostat; Hyperuricemia; Imino Furanoses; Inosine; Macaca mulatta; Male; Pyrimidinones; Reproducibility of Results; Uric Acid | 2021 |
[Gout].
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid | 2021 |
Formulation and Characterization of Febuxostat Loaded Nanostructured Lipid Carriers (NLCs) - Gel for Topical Treatment of Gout.
Topics: Drug Carriers; Febuxostat; Gout; Humans; Hyperuricemia; Lipids; Nanostructures; Particle Size; Polymers | 2022 |
Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.
Topics: Animal Structures; Animals; Diabetes Mellitus; Febuxostat; Gene Expression Profiling; Gout Suppressants; Hyperuricemia; Immunohistochemistry; Intra-Abdominal Fat; Mice; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Stress, Physiological; Thrombosis; Xanthine Oxidase | 2017 |
Management of Gout and Hyperuricemia in CKD.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Symptom Flare Up; Treatment Outcome; Uric Acid | 2017 |
Multiple Gouty Tophi with Bone Erosion and Destruction: A Report of an Early-onset Case in an Obese Patient.
Topics: Adult; Arthritis, Gouty; Cytokines; Febuxostat; Gout Suppressants; Hand; Humans; Hyperuricemia; Knee Joint; Male; Obesity; Treatment Outcome | 2017 |
Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid | 2017 |
[Effect of febuxostat on epithelial-to-mesenchymal transition of kidney tubules, serum interleukin-6 and transforming growth factor β(1) in hyperuricemic rats].
Topics: Animals; Antigens, CD; Cadherins; Chalcone; Creatinine; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition; Febuxostat; Gout Suppressants; Hyperuricemia; Interleukin-6; Kidney Tubules; Male; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Transforming Growth Factor beta1; Uric Acid | 2017 |
Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Comorbidity; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Japan; Longitudinal Studies; Male; Middle Aged; Prevalence; Renal Agents; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Sex Distribution; Treatment Outcome; Uric Acid; Vascular Diseases; Young Adult | 2017 |
Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Topics: Adult; Aged; Febuxostat; Female; Follow-Up Studies; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Prospective Studies; Pyridines; Renal Dialysis; Uric Acid; Uricosuric Agents | 2017 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Incidence; Male; Middle Aged; Renal Insufficiency, Chronic; Taiwan; Uric Acid; Uricosuric Agents | 2018 |
Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
Topics: Adult; Aged; Biomarkers; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Medical Records; Middle Aged; Retrospective Studies; Risk Factors; Seoul; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2018 |
Risk of Heart-Related Death From Gout Medication.
Topics: Cardiovascular Diseases; Cause of Death; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; United States; United States Food and Drug Administration | 2018 |
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Humans; Hyperuricemia; Models, Theoretical; Precision Medicine; Thioglycolates; Triazoles; Uric Acid; Uricosuric Agents | 2018 |
Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
Topics: Allopurinol; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Thioglycolates; Triazoles | 2018 |
A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
Topics: Adult; Allopurinol; China; Cost-Benefit Analysis; Febuxostat; Female; Gene Frequency; Genetic Testing; Gout; Gout Suppressants; HLA-B Antigens; Humans; Hyperuricemia; Male; Middle Aged; Precision Medicine; Retrospective Studies; Treatment Outcome | 2018 |
The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Topics: Adult; Aged; Allopurinol; Blood Pressure; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2018 |
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Febuxostat; Female; General Practitioners; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Medication Adherence; Middle Aged; Netherlands; Retrospective Studies; Rheumatologists; Uricosuric Agents; Young Adult | 2018 |
Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Down-Regulation; Drug Resistance; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Odds Ratio; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Uric Acid; Young Adult | 2018 |
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Topics: Allopurinol; Cardiovascular Diseases; Comorbidity; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Mortality; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Xanthine Oxidase | 2018 |
Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients.
Topics: Adult; Aged; Body Weight; Comorbidity; Datasets as Topic; Diabetes Mellitus; Dose-Response Relationship, Drug; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Models, Biological; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2018 |
[Design, synthesis and biological evaluation of oxadiazole derivatives as xanthine oxidase inhibitors].
Topics: Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Oxadiazoles; Xanthine Oxidase | 2016 |
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cause of Death; Databases, Factual; Febuxostat; Female; Gout; Hospitalization; Humans; Hyperuricemia; Male; Medicare; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Humans; Hydrogen Bonding; Hyperuricemia; Ligands; Luteolin; Millets; Molecular Docking Simulation; Molecular Dynamics Simulation; Principal Component Analysis; Quercetin; Xanthine Dehydrogenase | 2018 |
Febuxostat for the treatment of hyperuricaemia in gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2018 |
Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Dementia; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Incidence; Male; Propensity Score; Proportional Hazards Models; Retrospective Studies | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Severity of Illness Index; Uric Acid; Uricosuric Agents | 2018 |
Prescribing patterns of allopurinol and febuxostat according to directives on the reimbursement criteria and clinical guidelines: analysis of a primary care database.
Topics: Allopurinol; Databases, Factual; Febuxostat; Humans; Hyperuricemia; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Reimbursement Mechanisms; Retrospective Studies | 2019 |
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?
Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Topics: Adolescent; Adult; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Time Factors; Transplant Recipients; Treatment Outcome; Uric Acid; Young Adult | 2019 |
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Allopurinol; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Uric Acid | 2019 |
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; Prevalence; Probenecid; United States; Uric Acid; Uricosuric Agents; Young Adult | 2019 |
Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients.
Topics: Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged | 2019 |
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.
Topics: Adolescent; Adult; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Child; Child, Preschool; Cohort Studies; Czech Republic; Febuxostat; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Young Adult | 2019 |
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insufficiency, Chronic; Republic of Korea; Treatment Outcome; Uric Acid | 2020 |
Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
Topics: Adult; Aged; Biomarkers; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Patient Outcome Assessment; Propensity Score; Public Health Surveillance; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2019 |
Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.
Topics: Adult; Allografts; Allopurinol; Drug Substitution; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Transplantation; Male; Middle Aged; Transplant Recipients; Treatment Outcome; Uric Acid | 2019 |
[Case presentation--tophaceous gout].
Topics: Aged, 80 and over; Arthritis, Gouty; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Gout Suppressants; Hand Deformities, Acquired; Humans; Hyperuricemia; Mobility Limitation; Thiazoles; Uric Acid | 2012 |
Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Neutropenia; Renal Insufficiency, Chronic; Thiazoles | 2013 |
Cost-effectiveness of febuxostat in chronic gout.
Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiazoles; Uric Acid | 2014 |
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid | 2014 |
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medication Adherence; Primary Health Care; Risk Factors; Severity of Illness Index; Thiazoles; United States; Uric Acid | 2014 |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Topics: Adult; Aged; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Thiazoles; Uric Acid; Xanthine Oxidase | 2014 |
Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease.
Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic; Rhabdomyolysis; Thiazoles | 2014 |
Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure.
Topics: Adrenal Cortex Hormones; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Drug Therapy, Combination; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2014 |
Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Thiazoles; Xanthine Oxidase | 2014 |
Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.
Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Hospitalization; Humans; Hyperuricemia; Male; Prevalence; Thiazoles; Xanthine Oxidase | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Blood Glucose; Carbamates; Colchicine; Diabetes Mellitus, Type 2; Febuxostat; Glycated Hemoglobin; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoglycemic Agents; Insulin; Interleukin 1 Receptor Antagonist Protein; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uric Acid | 2015 |
Treat to target in gout by combining two modes of action.
Topics: Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Thioglycolates; Triazoles | 2014 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Disease Progression; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
Efficacy and safety of febuxostat in elderly female patients.
Topics: Aged; Comorbidity; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Retrospective Studies; Thiazoles; Treatment Outcome | 2014 |
Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry.
Topics: Aged; Aged, 80 and over; Allopurinol; Cross-Sectional Studies; Febuxostat; Female; Gout Suppressants; Hospitals; Humans; Hyperuricemia; Inappropriate Prescribing; Italy; Male; Patient Admission; Patient Discharge; Registries; Risk; Thiazoles; Xanthine Oxidase | 2014 |
Effects of Febuxostat on Oxidative Stress.
Topics: Adult; Aged; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Uric Acid | 2015 |
The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Topics: Animals; Apoptosis; Choline Deficiency; Cytoprotection; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hyperuricemia; Liver; Liver Cirrhosis, Experimental; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Carotid Artery Thrombosis; Case-Control Studies; Cell-Derived Microparticles; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Interleukin-6; Male; Middle Aged; Uric Acid; Xanthine Oxidase | 2015 |
Is It Time to Start Treating Asymptomatic Hyperuricemia?
Topics: Asymptomatic Diseases; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic | 2015 |
Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
Topics: Allopurinol; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Models, Econometric; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Insufficiency; Spain | 2016 |
Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis.
Topics: Adipose Tissue; Animals; Apoptosis; Carrier Proteins; Chondrocytes; Diet, High-Fat; Enzyme Activation; Enzyme Inhibitors; Febuxostat; Hyperuricemia; Inflammasomes; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; NLR Family, Pyrin Domain-Containing 3 Protein; Osteoarthritis; Osteophyte; RNA, Messenger; Synovial Membrane; Uric Acid; Xanthine Dehydrogenase | 2016 |
[Drug reduction of uric acid not just when symptoms appear].
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Humans; Hyperuricemia; Uric Acid | 2016 |
Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Topics: Aged; Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hypertension; Hyperuricemia; Kidney; Male; Middle Aged; Renin-Angiotensin System; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2016 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
Fixed drug eruption-like macules caused by febuxostat.
Topics: Adult; Drug Eruptions; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia | 2016 |
Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Topics: Computer Simulation; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Renal Insufficiency, Chronic; Uric Acid; Xanthine; Xanthine Oxidase | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
Febuxostat in Hyperuricemic Patients With Advanced CKD.
Topics: Adult; Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index | 2016 |
The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin's lymphoma
.
Topics: Adult; Aged; Aged, 80 and over; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Tumor Lysis Syndrome | 2016 |
The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats.
Topics: Animals; Anion Transport Proteins; Apoptosis; Calcineurin Inhibitors; Disease Models, Animal; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Transplantation; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tacrolimus | 2017 |
Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Topics: Aged; Aged, 80 and over; Drug Substitution; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Proteinuria; Pyridines; Renal Insufficiency, Chronic; Treatment Outcome; Xanthine Dehydrogenase; Xanthine Oxidase | 2017 |
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Febuxostat : a viewpoint by Naomi Schlesinger.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Febuxostat : a viewpoint by N. Lawrence Edwards.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Febuxostat.
Topics: Chronic Disease; Drug Approval; European Union; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2009 |
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2009 |
Gout Study Group: update on hyperuricemia and gout.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Prednisone; Prevalence; Thiazoles; United States; Uric Acid | 2009 |
Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Topics: Allopurinol; Drug Approval; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Chronic Disease; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2010 |
Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Topics: Animals; Apoptosis; Endoplasmic Reticulum Stress; Febuxostat; Hyperuricemia; Kidney; Kidney Tubules; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2012 |
Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules.
Topics: Allopurinol; Animals; Desensitization, Immunologic; Drug Hypersensitivity; Febuxostat; Gout; Humans; Hyperuricemia; Product Surveillance, Postmarketing; Recombinant Proteins; Skin; Thiazoles; Urate Oxidase | 2013 |
Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.
Topics: Aged; Aged, 80 and over; Biomarkers; Drug Monitoring; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Thiazoles; Time Factors; Treatment Outcome; Uric Acid | 2013 |
Febuxostat--treatment for hyperuricemia and gout?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
[Febuxostat versus allopurinol for hyperuricemia].
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles | 2006 |
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Topics: Animals; Blood Pressure; Febuxostat; Follow-Up Studies; Gout Suppressants; Hypertension, Renal; Hyperuricemia; Kidney Glomerulus; Male; Oxonic Acid; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazoles; Uric Acid; Xanthine Oxidase | 2008 |
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Topics: Animals; Disease Models, Animal; Febuxostat; Hyperuricemia; Kidney; Kidney Failure, Chronic; Male; Microcirculation; Nephrectomy; Oxonic Acid; Rats; Rats, Wistar; Recovery of Function; Thiazoles; Treatment Outcome | 2008 |